Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Immunoglobulin heavy diversity 2-21 (IGHD2-21)
- Target
- IGHD2-21
- Molecular classification
- Other (Immunoglobulin heavy chain gene segment, Diversity segment of V(D)J recombination)
01
Overview
Immunoglobulin heavy diversity 2-21 (IGHD2-21) is one of several diversity (D) gene segments located in the immunoglobulin heavy chain locus on chromosome 14 (14q32.33)[2][4]. During B cell development, IGHD2-21 can be recombined with variable (V) and joining (J) gene segments to form the variable region of the immunoglobulin heavy chain, a critical component of the antigen-binding site of antibodies[2]. This V(D)J recombination process underlies the immense diversity of the adaptive immune response, enabling the recognition of a vast array of antigens. Polymorphisms and structural variants in the IGH locus, including diversity segments like IGHD2-21, can influence the composition and function of an individual's antibody repertoire, affecting susceptibility to infections, responsiveness to vaccines, and potentially autoimmune diseases[3]. However, IGHD2-21 is not a stand-alone therapeutic target, receptor, or enzyme, but rather a genetic building block for antibody generation.
- Other names
- IGHD221IGHD2-21
02
Biological functions
Immune responseAntibody gene rearrangementGeneration of antibody diversity
03
Disease associations
Other (polymorphisms and structural variants in this locus can influence disease-related immune responses[3])
Beyond the preview
Go deeper on Immunoglobulin heavy diversity 2-21 (IGHD2-21).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Immunoglobulin heavy diversity 2-21 (IGHD2-21).